Overview
Raised: $833,148
Total Commitments ($USD)
Dealmaker Securities
12/11/2022
Not Provided
$1,500
Equity - Common
Series A
RegA+
$1.50
$68,195,651
Rolling Commitments ($USD)
12/30/2023
$2,270
118
2018
Healthcare & Pharmaceuticals
HealthTech
B2B/B2C
Medium
High
Balance Sheet
|
Cash and Cash Equivalents |
$6,143,513 |
|
Accounts and Notes Receivable |
$54,611 |
| Total Assets |
$6,411,228 |
|
Accounts Payable & Accrued Liabilities |
$403,212 |
|
Long Term Debt |
$0 |
|
Total Liabilities |
$6,411,228 |
|
Total Stockholders' Equity |
$6,008,016 |
| Total Liabilities and Equity |
$6,411,228 |
Statement of Comprehensive Income Information
|
Depreciation and Amortization |
$6,552 |
| Net Income |
$-3,520,134 |
|
Earnings Per Share - Basic |
$-0.09 |
|
Earnings Per Share - Diluted |
$-0.09 |
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| Shackelford Pharma | 12/13/2023 | Dealmaker Securities | $68,195,651 | $833,148 | Equity - Common | Funded | RegA+ |
| Shackelford Pharma | 08/19/2021 | Dalmore Group | $37,595,931 | $9,303,845 | Equity - Common | Funded | RegA+ |
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
